N-methyl-d-aspartate (NMDA) receptor genetics: The power of paralog homology and protein dynamics in defining dominant genetic variants.
NMDA
VUS
dominant negative
Journal
American journal of medical genetics. Part A
ISSN: 1552-4833
Titre abrégé: Am J Med Genet A
Pays: United States
ID NLM: 101235741
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
05
10
2021
received:
11
05
2021
accepted:
07
10
2021
pubmed:
3
11
2021
medline:
8
4
2022
entrez:
2
11
2021
Statut:
ppublish
Résumé
Predicting genotype-to-phenotype correlations from genomic variants has been challenging, particularly for genes that have a complex balance of dominant and recessive inheritance for phenotypes. Variants in NMDA receptor components GRIN1, GRIN2A, and GRIN2B cause a myriad of dominant disease phenotypes, with the most common being epilepsy and autism spectrum disorder. Starting from the analysis of a variant of uncertain significance (VUS, GRIN2A G760S), we realized the need for tools to map dominant variants for the components of the NMDA receptor. Some variants within GRIN1, GRIN2A, and GRIN2B exert dominant epilepsy and developmental delay, yet other amino acid variants are conserved and predicted to alter protein function but do not have dominant phenotypes. Common variant annotation tools are not powered to determine pathogenic dominant outcomes. To address this gap, we integrated sequence and structural analyses for GRIN1, GRIN2A, and GRIN2B. Using this approach, we determined that paralog homology mapping and topology can segregate dominant variants, with an elevation of intermolecular contacts between the subunits. Furthermore, demonstrating the general utility of our methodology, we show that 25 VUS within ClinVar also reach a dominant variant annotation, including the GRIN2A G760S variant. Our work suggests paralog homology and protein topology as a powerful strategy within the receptor complex to resolve dominant genetic variants relative to variants that would fit a recessive inheritance, requiring two damaging variants. These strategies should be tested in additional dominant genetic disorders to determine the broader utility.
Identifiants
pubmed: 34726335
doi: 10.1002/ajmg.a.62554
pmc: PMC10472328
mid: NIHMS1752067
doi:
Substances chimiques
Receptors, N-Methyl-D-Aspartate
0
N-Methylaspartate
6384-92-5
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
556-568Subventions
Organisme : NIEHS NIH HHS
ID : K01 ES025435
Pays : United States
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Bioinformatics. 2007 Nov 1;23(21):2947-8
pubmed: 17846036
Nucleic Acids Res. 2003 Jul 1;31(13):3812-4
pubmed: 12824425
Nat Genet. 2013 Sep;45(9):1067-72
pubmed: 23933819
Mol Genet Metab. 2014 Nov;113(3):161-70
pubmed: 24863970
Nature. 2014 Jul 10;511(7508):191-7
pubmed: 25008524
Mol Biol Evol. 2011 Oct;28(10):2731-9
pubmed: 21546353
Nature. 1987 Sep 17-23;329(6136):219-22
pubmed: 2442619
Neurology. 2016 Jun 7;86(23):2171-8
pubmed: 27164704
Science. 2017 Mar 24;355(6331):
pubmed: 28232581
Am J Hum Genet. 2016 Dec 1;99(6):1261-1280
pubmed: 27839871
Bioinformatics. 2015 Mar 1;31(5):761-3
pubmed: 25338716
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Mol Biol Evol. 1993 May;10(3):512-26
pubmed: 8336541
Proteins. 2009;77 Suppl 9:114-22
pubmed: 19768677
Nat Genet. 2019 Jan;51(1):12-18
pubmed: 30478442
Brain Dev. 2018 Mar;40(3):205-210
pubmed: 29056244
Hum Mutat. 2015 May;36(5):513-23
pubmed: 25684150
J Am Soc Nephrol. 2018 May;29(5):1525-1535
pubmed: 29476007
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Bioinformatics. 2015 Aug 15;31(16):2745-7
pubmed: 25851949
JAMA. 2014 Nov 12;312(18):1870-9
pubmed: 25326635
PLoS One. 2017 Feb 9;12(2):e0170818
pubmed: 28182669
Nucleic Acids Res. 2016 Jan 4;44(D1):D862-8
pubmed: 26582918
PLoS Genet. 2017 Jan 17;13(1):e1006536
pubmed: 28095420
Epilepsia. 2015 Jun;56(6):841-8
pubmed: 25864721
BMC Neurosci. 2008 Jan 15;9:6
pubmed: 18197970
Nat Genet. 2013 Sep;45(9):1061-6
pubmed: 23933820
Mol Autism. 2013 Oct 03;4(1):36
pubmed: 24090431
Hum Genet. 2021 Mar;140(3):423-439
pubmed: 32734384
N Engl J Med. 2012 Nov 15;367(20):1921-9
pubmed: 23033978
Nature. 1986 May 29-Jun 4;321(6069):519-22
pubmed: 3012362
Neurosci Lett. 2012 Mar 23;512(2):89-93
pubmed: 22326929
Mol Pharmacol. 2015 Jul;88(1):203-17
pubmed: 25904555
Nat Protoc. 2013 Aug;8(8):1494-512
pubmed: 23845962
Science. 2014 May 30;344(6187):992-7
pubmed: 24876489
Eur J Med Genet. 2017 Jun;60(6):317-320
pubmed: 28389307
Bioinformatics. 2005 Mar 1;21(5):676-9
pubmed: 15509596
J Mol Model. 2017 Mar;23(3):75
pubmed: 28204942
J Comput Chem. 2003 Dec;24(16):1999-2012
pubmed: 14531054
Mol Biol Evol. 1994 Sep;11(5):715-24
pubmed: 7968485